Comparison of Dual-antiplatelet Therapy to Mono-antiplatelet Therapy After Transcatheter Aortic Valve Implantation: Systematic Review and Meta-analysis

Canadian Journal of Cardiology

Volumn 31, Issue 6, 2015, Pages 775-784

  Gandhi, Sumeet ^a   Schwalm, Jon David R ^a   Velianou, James L ^a   Natarajan, Madhu K ^a   Farkouh, Michael E ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ANTICOAGULANT THERAPY; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; DUAL ANTIPLATELET THERAPY; HEART INFARCTION; HUMAN; ISCHEMIA; META ANALYSIS; MONO ANTIPLATELET THERAPY; OBSERVATIONAL STUDY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TRANSCATHETER AORTIC VALVE IMPLANTATION; TREATMENT OUTCOME; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; AORTIC VALVE STENOSIS; COMPARATIVE STUDY; DRUG COMBINATION; ECHOGRAPHY; FEMALE; MALE; MORTALITY; MYOCARDIAL INFARCTION; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; STROKE; SURVIVAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AORTIC VALVE STENOSIS; ASPIRIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; STROKE; SURVIVAL ANALYSIS; TICLOPIDINE; TRANSCATHETER AORTIC VALVE REPLACEMENT; TREATMENT OUTCOME;

EID: 84929838620     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2015.01.014     Document Type: Review

References (29)

1. Webb J., Rodes-Cabau J., Fremes S., et al. Transcatheter aortic valve implantation: a Canadian Cardiovascular Society position statement. Can J Cardiol 2012, 28:520-528.
2. Leon M.B., Smith C.R., Mack M., et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. NEngl J Med 2010, 363:1597-1607.
3. Noble S., Asgar A., Cartier R., Virmani R., Bonan R. Anatomo-pathological analysis after CoreValve Revalving system implantation. Eurointervention 2009, 5:78-85.
4. Nishimura R.A., Otto C.M., Bonow R.O., et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JAm Coll Cardiol 2014, 63:e57-e185.
5. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS One 2009, 6:e1000097.
6. Riley R.D., Higgins J.P., Deeks J.J. Interpretation of random effects meta-analyses. BMJ 2011, 342:d549.
7. Seiffert M., Conradi L., Terstesse A.C., et al. Blood transfusion is associated with impaired outcome after transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2015, 85:460-467.
8. Czerwinska-Jelonkiewicz K., Witkowski A., Dabrowski M., et al. Antithrombotic therapy-predictor of early and long-term bleeding complications after transcatheter aortic valve implantation. Arch Med Sci 2013, 9:1062-1070.
9. Griese D.P., Reents W., Diegeler A., Kerber S., Babin-Ebell J. Simple, effective and safe vascular access site closure with the double-ProGlide preclose technique in 162 patients receiving transfemoral transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2013, 82:E734-E741.
10. Schwerg M., Baldenhofer G., Dreger H., et al. Complete atrioventricular block after TAVI: when is pacemaker implantation safe?. Pacing Clin Electrophysiol 2013, 36:898-903.
11. Godino C., Pavon A.G., Mangieri A., Margonato A. Aortic valvuloplasty as bridging for TAVI in high-risk patients with Heyde's syndrome: a case report. Case Rep Med 2012, 2012:946764.
12. Stepinska J., Czerwinska K., Witkowski A., et al. Risk factors for bleeding complications in patients undergoing transcatheter aortic valve implantation (TAVI). Cardiol J 2013, 20:125-133.
13. Salinas P., Moreno R., Calvo L., et al. Clinical and prognostic implications of atrial fibrillation in patients undergoing transcatheter aortic valve implantation. World J Cardiol 2012, 4:8-14.
14. Collet J.P., Montalescot G. Antithrombotic and antiplatelet therapy in TAVI patients: a fallow field?. Eurointervention 2013, (9 suppl):S43-S47.
15. Delewi R., Piek J.J. Antiplatelet therapy following TAVI: time to randomise. Neth Heart J 2014, 22:62-63.
16. Meier P., Timmis A. Almanac 2012: Interventional Cardiology. The National Society Journals present selected research that has driven recent advances in clinical cardiology. Hellenic J Cardiol 2013, 54:242-254.
17. Rodes-Cabau J., Dauerman H.L., Cohen M.G., et al. Antithrombotic treatment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events. JAm Coll Cardiol 2013, 62:2349-2359.
18. Fusari M. Clopidogrel, aspirin and proton pump inhibition after percutaneous valve implants: an update. Curr Pharm Des 2013, 19:3932-3945.
19. Gerber R.T., Osborn M., Mikhail G.W. Delayed mortality from aortic dissection post transcatheter aortic valve implantation (TAVI): the tip of the iceberg. Catheter Cardiovasc Interv 2010, 76:202-204.
20. Gonyea E.F. The abnormal pupil in Cheyne-Stokes respiration. Case report. JNeurosurg 1990, 72:810-812.
21. Lynch D.R., Dantzler D., Robbins M., Zhao D. Considerations in antithrombotic therapy among patients undergoing transcatheter aortic valve implantation. JThromb Thrombolysis 2013, 35:476-482.
22. Meier P., Timmis A. Almanac 2012: interventional cardiology: the national society journals present selected research that has driven recent advances in clinical cardiology. Heart Dec 2012, 98:1701-1709.
23. Aryal M.R., Karmacharya P., Pandit A., et al. Dual versus single antiplatelet therapy in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis. Heart Lung Circ 2015, 24:185-192.
24. Durand E., Blanchard D., Chassaing S., et al. Comparison of two antiplatelet therapy strategies in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2014, 113:355-360.
25. Poliacikova P., Cockburn J., de Belder A., Trivedi U., Hildick-Smith D. Antiplatelet and antithrombotic treatment after transcatheter aortic valve implantation-comparison of regimes. JInvasive Cardiol 2013, 25:544-548.
26. Stabile E., Pucciarelli A., Cota L., et al. SAT-TAVI (single antiplatelet therapy for TAVI) study: a pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. Int J Cardiol 2014, 174:624-627.
27. Ussia G.P., Scarabelli M., Mule M., et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2011, 108:1772-1776.
28. Nashef S.A., Roques F., Michel P., et al. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999, 16:9-13.
29. O'Brien S.M., Shahian D.M., Filardo G., et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2-isolated valve surgery. Ann Thorac Surg 2009, 88(1 suppl):S23-S42.